Celldex Therapeutics is a clinical-stage biopharma company specializing in monoclonal and bispecific antibodies targeting mast cell-driven diseases. Its lead candidate, Barzolvolimab, is in Phase 3 trials for Chronic Spontaneous Urticaria and other urticarias, with Phase 2 studies underway in Prurigo Nodularis and Atopic Dermatitis. The company has no approved products or meaningful revenues, reflecting continued heavy operating losses and negative cash flow as it invests heavily in R&D. Despite liquidity of approximately $519 million at end-2025, Celldex anticipates the need for additional funding to complete development and support future commercialization efforts. Risks include regulatory approvals, competitive landscape, capital requirements, and operational execution.